While antibiotics may offer certain cardiometabolic benefits by modulating gut microbiota, their widespread use remains debatable due to potential risks
According to FDA prescribing information, gastrointestinal side effects are typically mild to moderate in severity and tend to diminish over time as patients develop tolerance to the medication
Food and Drug Administration (FDA) and the European Medicines Agency (EMA) respectively concurred with a pharmaceutical company on the efficacy endpoints for two distinct clinical indications of arhalofenate in 2017
Evidence that hydrated electrons, nitrogen-centered radicals, and OH radicals trigger DNA damage: a combined photocleavage and laser flash photolysis study
exclusivity (Times of India, 2025), mirror Indias aggressive generic strategy
The 2020 update of the CEAP classification system and reporting standards